Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group
- PMID: 11099087
- DOI: 10.1097/00006454-200011000-00007
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group
Abstract
Background: Respiratory syncytial virus (RSV) remains a significant cause of morbidity, especially in premature infants and immunocompromised children, resulting in approximately 100 000 hospitalizations annually. A study was performed to evaluate the outcomes of those given palivizumab (Synagis; MedImmune, Inc., Gaithersburg, MD) during the 1998 to 1999 RSV season, its first season in general use.
Methods: A retrospective chart review of 1839 patients from 9 United States sites was conducted, representing all patients given palivizumab at each site. Those evaluated were to have a gestational age of < or =35 weeks, were to be <2 years old at their first injection and were to have received at least one dose of palivizumab (humanized monoclonal antibody against RSV) between September, 1998, and May, 1999. Gestational age, comorbidities, frequency of injections, hospitalizations and length of hospital stays were assessed.
Results: The antigen- or culture-positive RSV hospitalization rates for those given prophylaxis were 2.3% (42 of 1839) overall, 16/399 (4.0%) with chronic lung disease of infancy and 26 of 1227 (2.1%) born prematurely without chronic lung disease of infancy. Twenty-six patients had a gestational age of >35 weeks and were included in the analysis.
Conclusions: Only 2.3% of children receiving palivizumab prophylaxis were hospitalized with RSV lower respiratory infection. This compares favorably with the rates observed in the pivotal trial (IMpact-RSV trial in 1996 to 1997), in which prophylaxis reduced hospitalization from 10.6% in the placebo group to 4.8% in those children receiving prophylaxis.
Similar articles
-
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84. Pediatr Infect Dis J. 2003. PMID: 12671452
-
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.Pediatr Pulmonol. 2003 Jun;35(6):484-9. doi: 10.1002/ppul.10288. Pediatr Pulmonol. 2003. PMID: 12746948
-
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46. J Manag Care Pharm. 2010. PMID: 20131495 Free PMC article. Review.
-
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050. Health Technol Assess. 2011. PMID: 21281564 Free PMC article. Review.
-
Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.Pediatr Infect Dis J. 2002 Jun;21(6):512-8. doi: 10.1097/00006454-200206000-00007. Pediatr Infect Dis J. 2002. PMID: 12182374 Clinical Trial.
Cited by
-
Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.Am J Perinatol. 2024 May;41(S 01):e1107-e1115. doi: 10.1055/a-1990-2633. Epub 2022 Nov 30. Am J Perinatol. 2024. PMID: 36452969 Free PMC article.
-
Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice.Vaccines (Basel). 2020 Nov 2;8(4):638. doi: 10.3390/vaccines8040638. Vaccines (Basel). 2020. PMID: 33147726 Free PMC article.
-
Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014).Dev Period Med. 2018;22(4):308-314. doi: 10.34763/devperiodmed.20182204.308314. Dev Period Med. 2018. PMID: 30636227 Free PMC article.
-
Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Infect Dis Ther. 2018 Mar;7(1):87-120. doi: 10.1007/s40121-018-0188-z. Epub 2018 Feb 22. Infect Dis Ther. 2018. PMID: 29470837 Free PMC article. Review.
-
The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.Hum Vaccin Immunother. 2017 Mar 4;13(3):599-606. doi: 10.1080/21645515.2016.1235670. Epub 2016 Oct 21. Hum Vaccin Immunother. 2017. PMID: 27768505 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical